The stage classification of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines

Chest

Volumn 143, Issue 5 SUPPL, 2013, Pages

  Detterbeck, Frank C ^a   Postmus, Pieter E ^b   Tanoue, Lynn T ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PRACTICE; EVIDENCE BASED MEDICINE; FALSE NEGATIVE RESULT; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CANCER; LUNG NODULE; LUNG RESECTION; LUNG SMALL CELL CANCER; LYMPH NODE METASTASIS; MEDICAL HISTORY; MINIMAL RESIDUAL DISEASE; MULTIPLE CANCER; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT LARYNGEAL NERVE PALSY; SECOND CANCER; SENTINEL LYMPH NODE BIOPSY; TUMOR INVASION; TUMOR VOLUME;

EID: 84877655821     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-2354     Document Type: Article

References (110)

1. Lewis SZ, Diekemper R, Addrizzo-Harris DJ. Methodology for development of guidelines for lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143 (5)(suppl): 41S-50S.
2. Groome PA, Bolejack V, Crowley JJ, et al; IASLC International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007; 2 (8): 694-705.
3. Union Internationale Contre le Cancer. TNM Classification of Malignant Tumors. 7th ed. Hoboken, NJ : Wiley-Blackwell; 2009.
4. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th ed. New York, NY : Springer; 2009.
5. Wittekind C, ed. TNM Supplement: A Commentary on Uniform Use. 4th ed. London, England: John Wiley & Sons; 2012.
6. Goldstraw P, ed. IASLC Staging Manual in Thoracic Oncology. Orange Park, FL: Editorial Rx Press; 2009
7. Rami-Porta R, Ball D, Crowley J, et al; International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2007; 2 (7): 593-602.
8. Rusch VW, Crowley J, Giroux DJ, et al; International Association for the Study of Lung Cancer International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2007; 2(7):603-612.
9. Postmus PE, Brambilla E, Chansky K, et al; International Association for the Study of Lung Cancer International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol. 2007; 2 (8): 686-693.
10. Goldstraw P, Crowley J, Chansky K, et al; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007; 2 (8): 706-714.
11. Shepherd FA, Crowley J, Van Houtte P, et al; International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol. 2007; 2 (12): 1067-1077.
12. Travis WD, Giroux DJ, Chansky K, et al; International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2008; 3 (11): 1213-1223.
13. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009; 136 (1): 260-271.
14. Detterbeck FC, Boffa DJ, Tanoue LT, Wilson LD. Details and difficulties regarding the new lung cancer staging system. Chest. 2010; 137 (5): 1172-1180.
15. Hsu P-K, Huang H-C, Hsieh C-C, et al. Effect of formalin fixation on tumor size determination in stage I non-small cell lung cancer. Ann Thorac Surg. 2007; 84 (6): 1825-1829.
16. Yim J, Zhu L-C, Chiriboga L, Watson HN, Goldberg JD, Moreira AL. Histologic features are important prognostic indicators in early stages lung adenocarcinomas. Mod Pathol. 2007; 20 (2): 233-241.
17. Suzuki K, Yokose T, Yoshida J, et al. Prognostic significance of the size of central fibrosis in peripheral adenocarcinoma of the lung. Ann Thorac Surg. 2000; 69 (3): 893-897.
18. Maeshima AM, Niki T, Maeshima A, Yamada T, Kondo H, Matsuno Y. Modified scar grade: a prognostic indicator in small peripheral lung adenocarcinoma. Cancer. 2002; 95 (12): 2546-2554.
19. Travis W, Brambilla E, Noguchi M, et al. The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification. Paper presented at: 13th World Conference on Lung Cancer; August 4, 2009; San Francisco, CA.
20. Yokose T, Suzuki K, Nagai K, Nishiwaki Y, Sasaki S, Ochiai A. Favorable and unfavorable morphological prognostic factors in peripheral adenocarcinoma of the lung 3 cm or less in diameter. Lung Cancer. 2000; 29 (3): 179-188.
21. Kerr KM. Pulmonary adenocarcinomas: classification and reporting. Histopathology. 2009; 54 (1): 12-27.
22. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011; 24 (5): 653-664.
23. Travis WDMD, Brambilla EMD, Rami-Porta RMD, et al; International Staging Committee. Visceral pleural invasion: pathologic criteria and use of elastic stains: proposal for the 7th edition of the TNM classification for lung cancer. J Thorac Oncol. 2008; 3(12):1384-1390.
24. Rusch V, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P; Members of IASLC Staging Committee. The IASLC Lung Cancer Staging Project: a proposal for a new international lymph node map in the forthcoming 7th edition of the TNM classification for lung cancer. J Thorac Oncol. 2009; 4(5):568-577.
25. Detterbeck F, Jantz M, Wallace M, Vansteenkiste J, Silvestri GA; American College of Chest Physicians. Invasive mediastinal staging of lung cancer: ACCP evidence based clinical practice guidelines (2nd edition). Chest. 2007; 132(suppl 3):202S-220S.
26. Lardinois D, De Leyn P, Van Schil P, et al. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardiothorac Surg. 2006; 30 (5): 787-792.
27. Liptay MJMD, D'amico TAMD, Nwogu CMD, et al; Thoracic Surgery Subcommittee of the Cancer and Leukemia Group B. Intraoperative sentinel node mapping with technitium-99 in lung cancer: results of CALGB 140203 multicenter phase II trial. J Thorac Oncol. 2009; 4 (2): 198-202.
28. Rzyman W, Hagen OM, Dziadziuszko R, et al. Intraoperative, radio-guided sentinel lymph node mapping in 110 nonsmall cell lung cancer patients. Ann Thorac Surg. 2006; 82 (1): 237-242.
29. Ono T, Minamiya Y, Ito M, et al. Sentinel node mapping and micrometastasis in patients with clinical stage IA nonsmall cell lung cancer. Interact Cardiovasc Thorac Surg. 2009; 9 (4): 659-661.
30. Kim AW, Johnson KM, Detterbeck FC. The lung cancer stage page: there when you need it-staginglungcancer.org. Chest. 2012; 141 (3): 581-586.
31. Gould MK, Donington J, Lynch WR, et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143 (5)(suppl): e93S-e120S.
32. Keogan MT, Tung KT, Kaplan DK, Goldstraw PJ, Hansell DM. The significance of pulmonary nodules detected on CT staging for lung cancer. Clin Radiol. 1993; 48 (2): 94-96.
33. Kunitoh H, Eguchi K, Yamada K, et al. Intrapulmonary sublesions detected before surgery in patients with lung cancer. Cancer. 1992; 70 (7): 1876-1879.
34. Shen KR, Meyers BF, Larner JM, Jones DR; American College of Chest Physicians. Special treatment issues in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007; 132(3):290S-305S.
35. Cerfolio RJ, Bryant AS. Is palpation of the nonresected pulmonary lobe(s) required for patients with non-small cell lung cancer? A prospective study. J Thorac Cardiovasc Surg. 2008; 135 (2): 261-268.
36. Swensen SJ, Silverstein MD, Edell ES, et al. Solitary pulmonary nodules: clinical prediction model versus physicians. Mayo Clin Proc. 1999; 74 (4): 319-329.
37. Antakli T, Schaefer RF, Rutherford JE, Read RC. Second primary lung cancer. Ann Thorac Surg. 1995; 59 (4): 863-866.
38. Thomas PA Jr, Rubinstein L; The Lung Cancer Study Group. Malignant disease appearing late after operation for T1 N0 non-small-cell lung cancer. J Thorac Cardiovasc Surg. 1993; 106 (6): 1053-1058.
39. Pastorino U, Infante M, Maioli M, et al. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol. 1993; 11 (7): 1216-1222.
40. Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg. 1995; 109(1): 120-129.
41. Ribet M, Dambron P. Multiple primary lung cancers. Eur J Cardiothorac Surg. 1995; 9 (5): 231-236.
42. Van Meerbeeck J, Weyler J, Thibaut A, et al. Second primary lung cancer in Flanders: frequency, clinical presentation, treatment and prognosis. Lung Cancer. 1996; 15 (3): 281-295.
43. Levi F, Randimbison L, Te V-C, La Vecchia C. Second primary cancers in patients with lung carcinoma. Cancer. 1999; 86 (1): 186-190.
44. Tockman MS, Mulshine JL, Piantadosi S, et al. Prospective detection of preclinical lung cancer: results from two studies of heterogeneous ribonucleoprotein A2/B1 overexpression. Clin Cancer Res. 1997; 3 (12 pt 1): 2237-2246.
45. Ginsberg RJ, Rubinstein LV; Lung Cancer Study Group. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Ann Thorac Surg. 1995; 60 (3): 615-622.
46. Pairolero PC, Williams DE, Bergstralh EJ, Piehler JM, Bernatz PE, Payne WS. Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg. 1984; 38 (4): 331-338.
47. Saito Y, Sato M, Sagawa M, et al. Multicentricity in resected occult bronchogenic squamous cell carcinoma. Ann Thorac Surg. 1994; 57 (5): 1200-1205.
48. Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg. 1975; 70 (4): 606-612.
49. Detterbeck FC, Jones DR, Kernstine KH, Naunheim KS; American College of Physicians. Lung cancer. Special treatment issues. Chest. 2003; 123 (suppl 1): 244S-258S.
50. van Bodegom PC, Wagenaar SS, Corrin B, Baak JP, Berkel J, Vanderschueren RG. Second primary lung cancer: importance of long term follow up. Thorax. 1989; 44 (10): 788-793.
51. Mathisen DJ, Jensik RJ, Faber LP, Kittle CF. Survival following resection for second and third primary lung cancers. J Thorac Cardiovasc Surg. 1984; 88 (4): 502-510.
52. Deschamps C, Pairolero PC, Trastek VF, Payne WS. Multiple primary lung cancers. Results of surgical treatment. J Thorac Cardiovasc Surg. 1990; 99 (5): 769-777.
53. Rosengart TK, Martini N, Ghosn P, Burt M. Multiple primary lung carcinomas: prognosis and treatment. Ann Thorac Surg. 1991; 52 (4): 773-778.
54. Verhagen AFTM, Tavilla G, van de Wal HJCM, Cox AL, Lacquet LK. Multiple primary lung cancers. Thorac Cardiovasc Surg. 1994; 42 (1): 40-44.
55. Adebonojo SA, Moritz DM, Danby CA. The results of modern surgical therapy for multiple primary lung cancers. Chest. 1997; 112 (3): 693-701.
56. Okada M, Tsubota N, Yoshimura M, Miyamoto Y. Operative approach for multiple primary lung carcinomas. J Thorac Cardiovasc Surg. 1998; 115 (4): 836-840.
57. Wu SC, Lin ZQ, Xu CW, Koo KS, Huang OL, Xie DQ. Multiple primary lung cancers. Chest. 1987; 92 (5): 892-896.
58. De Leyn P, Moons J, Vansteenkiste J, et al. Survival after resection of synchronous bilateral lung cancer. Eur J Cardiothorac Surg. 2008; 34 (6): 1215-1222.
59. Lee JG, Lee CY, Kim DJ, Chung KY, Park IK. Non-small cell lung cancer with ipsilateral pulmonary metastases: prognosis analysis and staging assessment. Eur J Cardiothorac Surg. 2008; 33 (3): 480-484.
60. Riquet M, Cazes A, Pfeuty K, et al. Multiple lung cancers prognosis: what about histology? Ann Thorac Surg. 2008; 86 (3): 921-926.
61. Rostad H, Strand TE, Naalsund A, Norstein J. Resected synchronous primary malignant lung tumors: a populationbased study. Ann Thorac Surg. 2008; 85 (1): 204-209.
62. Battafarano RJ, Meyers BF, Guthrie TJ, Cooper JD, Patterson GA. Surgical resection of multifocal non-small cell lung cancer is associated with prolonged survival. Ann Thorac Surg. 2002; 74 (4): 988-993.
63. Detterbeck FC, Jones DR, Funkhouser WK Jr. Satellite nodules and multiple primary cancers. In: Detterbeck FC, Rivera MP, Socinski MA, et al, eds. Diagnosis and Treatment of Lung Cancer: an Evidence-Based Guide for the Practicing Clinician. Philadelphia, PA : W. B. Saunders; 2001 : 437-449.
64. Battafarano RJ, Force SD, Meyers BF, et al. Benefits of resection for metachronous lung cancer. J Thorac Cardiovasc Surg. 2004; 127 (3): 836-842.
65. Lee BE, Port JL, Stiles BM, et al. TNM stage is the most important determinant of survival in metachronous lung cancer. Ann Thorac Surg. 2009; 88 (4): 1100-1105.
66. Finley DJ, Yoshizawa A, Travis W, et al. Predictors of outcomes after surgical treatment of synchronous primary lung cancers. J Thorac Oncol. 2010; 5 (2): 197-205.
67. Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol. 2008; 32 (6): 810-827.
68. Russell PA, Wainer Z, Wright GM, Daniels M, Conron M, Williams RA. Does lung adenocarcinoma subtype predict patient survival? A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol. 2011; 6 (9): 1496-1504.
69. Sica G, Yoshizawa A, Sima CS, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol. 2010; 34 (8): 1155-1162.
70. Warth A, Muley T, Meister M, et al. The novel histologic International Association for the Study of Lung Cancer/Amer ican Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol. 2012; 30 (13): 1438-1446.
71. Wang X, Wang M, MacLennan GT, et al. Evidence for common clonal origin of multifocal lung cancers. J Natl Cancer Inst. 2009; 101 (8): 560-570.
72. Hiroshima K, Toyozaki T, Kohno H, Ohwada H, Fujisawa T. Synchronous and metachronous lung carcinomas: molecular evidence for multicentricity. Pathol Int. 1998; 48 (11): 869-876.
73. Huang J, Behrens C, Wistuba I, Gazdar AF, Jagirdar J. Molecular analysis of synchronous and metachronous tumors of the lung: impact on management and prognosis. Ann Diagn Pathol. 2001; 5 (6): 321-329.
74. Dacic SMDP, Ionescu DNMD, Finkelstein SMD, Yousem SA. Patterns of allelic loss of synchronous adenocarcinomas of the lung. Am J Surg Pathol. 2005; 29 (7): 897-902.
75. Chang Y-L, Wu C-T, Lin S-C, Hsiao CF, Jou YS, Lee YC. Clonality and prognostic implications of p53 and epidermal growth factor receptor somatic aberrations in multiple primary lung cancers. Clin Cancer Res. 2007; 13 (1): 52-58.
76. Girard ND, Deshpande C, Lau C, et al. Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Am J Surg Pathol. 2009; 33 (12): 1752-1764.
77. Girard N, Ostrovnaya I, Lau C, et al. Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. Clin Cancer Res. 2009; 15 (16): 5184-5190.
78. Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143 (5)(suppl): e211S-e250S.
79. Jett JR, Schild SE, Kesler KA, Kalemkerian GP. Treatment of small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143 (5)(suppl): e400S-e419S.
80. Asamura H, Goya T, Koshiishi Y, et al; Japanese Joint Committee of Lung Cancer Registry. A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol. 2008; 3 (1): 46-52.
81. Sawabata N, Miyaoka E, Asamura H, et al; Japanese Joint Committee for Lung Cancer Registration. Japanese lung cancer registry study of 11,663 surgical cases in 2004: demographic and prognosis changes over decade. J Thorac Oncol. 2011; 6 (7): 1229-1235.
82. Arenberg D; American College of Chest Physicians. Bronchioloalveolar lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007; 132(suppl 3): 306S-313S.
83. Garfield DH, Cadranel JL, Wislez M, Franklin WA, Hirsch FR. The bronchioloalveolar carcinoma and peripheral adenocarcinoma spectrum of diseases. J Thorac Oncol. 2006; 1 (4): 344-359.
84. Detterbeck FC, Jones DR, Funkhouser WK Jr. Bronchioloalveolar carcinoma. In: Detterbeck FC, Rivera MP, Socinski MA, et al, eds. Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician. Philadelphia, PA : W. B. Saunders; 2001 : 394-407.
85. Kakinuma R, Ohmatsu H, Kaneko M, et al. Progression of focal pure ground-glass opacity detected by low-dose helical computed tomography screening for lung cancer. J Comput Assist Tomogr. 2004; 28 (1): 17-23.
86. Nakata M, Sawada S, Yamashita M, et al. Surgical treatments for multiple primary adenocarcinoma of the lung. Ann Thorac Surg. 2004; 78 (4): 1194-1199.
87. Travis WD, Garg K, Franklin WA, et al. Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol. 2005; 23 (14): 3279-3287.
88. Sakuma Y, Matsukuma S, Yoshihara M, et al. Epidermal growth factor receptor gene mutations in atypical adenomatous hyperplasias of the lung. Mod Pathol. 2007; 20(9): 967-973.
89. Takashima S, Maruyama Y, Hasegawa M, et al. CT findings and progression of small peripheral lung neoplasms having a replacement growth pattern. AJR Am J Roentgenol. 2003; 180 (3): 817-826.
90. Kitamura H, Kameda Y, Nakamura N, et al. Atypical adenomatous hyperplasia and bronchoalveolar lung carcinoma. Analysis by morphometry and the expressions of p53 and carcinoembryonic antigen. Am J Surg Pathol. 1996; 20(5): 553-562.
91. Trousse D, Barlesi F, Loundou A, et al. Synchronous multiple primary lung cancer: an increasing clinical occurrence requiring multidisciplinary management. J Thorac Cardiovasc Surg. 2007; 133 (5): 1193-1200.
92. Kim HK, Choi YS, Kim J, Shim YM, Lee KS, Kim K. Management of multiple pure ground-glass opacity lesions in patients with bronchioloalveolar carcinoma. J Thorac Oncol. 2010; 5 (2): 206-210.
93. Miller RR, Nelems B, Evans KG, Müller NL, Ostrow DN. Glandular neoplasia of the lung. A proposed analogy to colonic tumors. Cancer. 1988; 61 (5): 1009-1014.
94. Ullmann R, Bongiovanni M, Halbwedl I, et al. Is high-grade adenomatous hyperplasia an early bronchioloalveolar adenocarcinoma? J Pathol. 2003; 201 (3): 371-376.
95. Wislez M, Massiani M-A, Milleron B, et al. Clinical characteristics of pneumonic-type adenocarcinoma of the lung. Chest. 2003; 123 (6): 1868-1877.
96. Akira M, Atagi S, Kawahara M, Iuchi K, Johkoh T. Highresolution CT findings of diffuse bronchioloalveolar carcinoma in 38 patients. AJR Am J Roentgenol. 1999; 173 (6): 1623-1629.
97. Park JH, Lee KS, Kim JH, et al. Malignant pure pulmonary ground-glass opacity nodules: prognostic implications. Korean J Radiol. 2009; 10 (1): 12-20.
98. López-Encuentra A, Duque-Medina JL, Rami-Porta R. Persistent confusion on the clinical and pathologic nodal staging in lung cancer. J Thorac Oncol. 2010; 5 (2): 285-286.
99. Rami-Porta R, López-Encuentra A, Duque-Medina JL. Caution! The latest AJCC's rules for lung cancer classification differ from the latest UICC's. Lung Cancer. 2004; 43 (3): 361-362.
100. Detterbeck FC. Integration of mediastinal staging techniques for lung cancer. Semin Thorac Cardiovasc Surg. 2007; 19(3): 217-224.
101. Silvestri G, Gould MK, Margolis ML, et al; American College of Chest Physicians. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007; 132(suppl 3):178S-201S.
102. Detterbeck F, Puchalski J, Rubinowitz A, Cheng D. Classification of the thoroughness of mediastinal staging of lung cancer. Chest. 2010; 137 (2): 436-442.
103. Hermanek P, Hutter RVP, Sobin LH, Wittekind C. International Union Against Cancer. Classification of isolated tumor cells and micrometastasis. Cancer. 1999; 86 (12): 2668-2673.
104. Osaki T, Oyama T, Gu C-D, et al. Prognostic impact of micrometastatic tumor cells in the lymph nodes and bone marrow of patients with completely resected stage I non-small-cell lung cancer. J Clin Oncol. 2002; 20 (13): 2930-2936.
105. Wu J, Ohta Y, Minato H, et al. Nodal occult metastasis in patients with peripheral lung adenocarcinoma of 2.0 cm or less in diameter. Ann Thorac Surg. 2001; 71 (6): 1772-1777.
106. Le Pimpec-Barthes F, Danel C, Lacave R, et al. Association of CK19 mRNA detection of occult cancer cells in mediastinal lymph nodes in non-small cell lung carcinoma and high risk of early recurrence. Eur J Cancer. 2005; 41 (2): 306-312.
107. Nosotti M, Falleni M, Palleschi A, et al. Quantitative realtime polymerase chain reaction detection of lymph node lung cancer micrometastasis using carcinoembryonic antigen marker. Chest. 2005; 128 (3): 1539-1544.
108. Maddaus M, Wang X, Vollmer R, et al. CALGB 9761: A prospective analysis of IHC and PCR based detection of occult metastatic disease in stage I NSCLC. J Clin Oncol, ASCO Annual Proceedings Part I. 2006; 24(18s):7030.
109. Marchevsky AM, Qiao J-H, Krajisnik S, Mirocha JM, McKenna RJ. The prognostic significance of intranodal isolated tumor cells and micrometastases in patients with nonsmall cell carcinoma of the lung. J Thorac Cardiovasc Surg. 2003; 126 (2): 551-557.
110. Boffa D, Detterbeck F, Smith E, et al. Should the 7th edition of the lung cancer stage classification system change treatment algorithms in NSCLC? J Thorac Oncol. 2010;5(11):1779-1783.